Rubius Therapeutics, Inc. (NASDAQ:RUBY) is reporting third quarter financial results on Monday 9th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, RUBY is expected to report 3Q20 loss of $ 0.49 per share.
For the full year, analysts anticipate loss of $ 2.07 per share bottom line.
Stock Performance
On Friday, shares of Rubius Therapeutics, Inc. has traded high as $ 4.63 and has cracked $ 4.39 on the downward trend, reaching $ 4.42 with volume of 189.30 thousand shares.
According to the previous trading day, closing price of $ 4.42, representing a 36.42 % increase from the 52 week low of $ 3.35 and a 68.35 % decrease over the 52 week high of $ 14.44.
The company has a market capital of $ 356.99 million and is part of the Healthcare sector and Biotechnology industry.
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
